Join Growin Stock Community!

Nextcure, inc.NXTC.US Overview

US StockHealthcare
(No presentation for NXTC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NXTC AI Insights

NXTC Overall Performance

NXTC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NXTC Recent Performance

-6.84%

Nextcure, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NXTC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NXTC Key Information

NXTC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NXTC Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Price of NXTC

NXTC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NXTC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-21.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.52
PB Ratio
1.92
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-21.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.52
PB Ratio
1.92
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NXTC's latest earnings report released?

    The most recent financial report for Nextcure, inc. (NXTC) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NXTC's short-term business performance and financial health. For the latest updates on NXTC's earnings releases, visit this page regularly.

  • How much cash does NXTC have?

    At the end of the period, Nextcure, inc. (NXTC) held Total Cash and Cash Equivalents of 7.32M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NXTC's EPS continuing to grow?

    According to the past four quarterly reports, Nextcure, inc. (NXTC)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NXTC?

    Nextcure, inc. (NXTC)'s Free Cash Flow (FCF) for the period is -6.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 46.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.